NAMSA Acquires Labcorp's Early Development Business, Expanding Services for MedTech Clients.
- NAMSA acquires Labcorp's Early Development business, enhancing its medical device testing and regulatory consulting services.
- The acquisition allows NAMSA to better support over 3,000 MedTech clients throughout the product lifecycle.
- NAMSA aims to maintain high service quality and client satisfaction during the integration of Labcorp's services.
NAMSA Expands Service Offerings with Acquisition of Labcorp's Early Development Business
In a significant strategic move, NAMSA, a leading global player in medical device testing and regulatory consulting, acquires Labcorp's Early Development medical device testing business. This acquisition not only broadens NAMSA’s service portfolio but also enhances its capability to support MedTech manufacturers throughout the product lifecycle. By integrating Labcorp's U.S. services, which encompass biocompatibility testing, microbiological testing, analytical testing, and preclinical research, NAMSA positions itself as a comprehensive partner for over 3,000 MedTech clients worldwide. NAMSA CEO Brian Smith emphasizes the commitment to providing Labcorp's clients with a seamless transition, ensuring high-quality service continuity during this significant operational shift.
The integration of Labcorp's services enables NAMSA to streamline solutions for its MedTech clientele, reinforcing its mission to advance innovation within the industry. This acquisition represents NAMSA's 10th since joining ARCHIMED, a healthcare-focused global private equity firm, in 2020. As NAMSA operates facilities in Ohio, Minnesota, Georgia, and California, it is poised to manage future projects for Labcorp's Early Development clients effectively. This expansion not only enhances NAMSA’s testing and consulting capabilities but also solidifies its role as a vital partner in accelerating medical device product development, crucial for improving healthcare outcomes.
Brian Caveney, EVP and President of Labcorp's Early Development Research Laboratories, expresses confidence in NAMSA’s ability to uphold high standards during the transition. This confidence allows Labcorp to refocus on its core preclinical drug development and chemical testing activities, indicating a strategic realignment that could benefit both organizations. Established in 1967, NAMSA has built a reputation for its extensive knowledge and resources in testing, clinical research, and regulatory compliance, making it an indispensable ally for medical device innovation.
In addition to enhancing its service offerings, NAMSA’s acquisition underscores the growing importance of regulatory consulting and testing in the medical device sector. As manufacturers face increasing scrutiny and regulatory requirements, having access to comprehensive testing services can significantly streamline the development process. The acquisition also reflects a broader trend within the industry, where consolidation is becoming a common strategy for companies aiming to enhance their competitive edge and service delivery.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

